HER2异质性乳腺癌模型揭示耐药演化中的新靶点与亚克隆动态
本研究建立源自同一肿瘤的ERBB2扩增(HER2hi)与非扩增(HER2lo)细胞群组成的HER2异质性乳腺癌模型,结合细胞条形码技术揭示HER2hi与HER2lo亚群间的亚克隆协作。HER2lo细胞驱动对HER2靶向抗体偶联药物(ADC)如T-DXd的耐药,但对HER2激酶抑制剂敏感;CRISPR筛选发现敲除ABCC1或USP9X可增敏HER2lo细胞对T-DXd的应答,抑制USP9X增强HER2溶酶体靶向并减少T-DXd治疗后复发。
要点
- HER2lo细胞驱动HER2异质性乳腺癌对T-DXd等HER2靶向ADC耐药。
- HER2lo细胞对HER2激酶抑制剂敏感,提示替代治疗策略。
- 抑制USP9X可增敏HER2lo细胞对T-DXd并减少复发。
核心结论
- HER2异质性乳腺癌中HER2lo细胞通过亚克隆协作驱动HER2靶向ADC耐药并加速复发。
- 抑制USP9X或ABCC1可增敏HER2lo细胞对T-DXd,为克服耐药提供新策略。
研究设计与样本
- 研究建立人HER2异质性乳腺癌模型,由同一肿瘤来源的ERBB2扩增(HER2hi)与非扩增(HER2lo)细胞群组成。
- 利用该模型结合细胞条形码技术及CRISPR筛选进行体外与体内研究。
主要发现
- HER2hi与HER2lo亚群间存在亚克隆协作。
- HER2lo细胞驱动对HER2靶向ADC(如T-DXd)的耐药,但对HER2激酶抑制剂敏感。
- CRISPR筛选在异质性共培养中鉴定出ABCC1和USP9X为HER2lo细胞对T-DXd的增敏靶点。
- 抑制USP9X增强HER2的溶酶体靶向,促进ADC载荷释放并减少T-DXd治疗后肿瘤复发。
临床怎么用
- HER2异质性乳腺癌患者对HER2靶向ADC耐药时,可考虑HER2激酶抑制剂。
- USP9X或ABCC1抑制联合T-DXd可能克服HER2lo细胞介导的耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Intratumor heterogeneity for human epidermal growth factor receptor 2 (HER2) in HER2-positive breast cancer is a driver of resistance to HER2-targeted therapies. The advancement of treatments for HER2 heterogeneous (HET) tumors has been hindered by the lack of preclinical models that accurately mimic the human disease. In this study, we describe human HER2 HET breast cancer models composed of ERBB2-amplified (HER2hi) and nonamplified (HER2lo) cell populations derived from the same tumor. Utilizing these models, together with cellular barcoding, we demonstrate subclonal cooperation between HER2hi and HER2lo subpopulations. Furthermore, HER2lo cells drive resistance to HER2-targeting antibody-drug conjugates (ADC) like trastuzumab deruxtecan (T-DXd) but are sensitive to HER2 kinase inhibitors. CRISPR screens in HET cocultures identified sensitizers of HER2lo cells to T-DXd, including ATP-binding cassette subfamily C member 1 and ubiquitin-specific peptidase 9 X (USP9X). USP9X inhibition enhances the lysosomal targeting of HER2, thereby potentiating ADC payload release and reducing tumor recurrence after T-DXd treatment. Our results elucidate the functional relevance of HER2 heterogeneity and propose improved therapies for these tumors. SIGNIFICANCE: Studies of HER2 HET breast cancer models demonstrated that HER2lo cells drive HER2-targeting ADC resistance and accelerate recurrence by cooperating with HER2hi cells. We identified novel therapeutic strategies to sensitize HER2lo cells to T-DXd, providing mechanistic insight and offering promising avenues to overcome resistance and improve patient outcomes.
引用
- Goyette MA, Graser C, Seehawer M, et al. HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies. Cancer Discov. 2026. PMID: 41925564. doi:10.1158/2159-8290.CD-25-1459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。